Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
160 hedge funds and large institutions have $1.76B invested in Aerie Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 65 increasing their positions, 56 reducing their positions, and 35 closing their positions.
67% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $7.3M
16% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 56
9% less funds holding
Funds holding: 176 → 160 (-16)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
40% less capital invested
Capital invested by funds: $2.96B → $1.76B (-$1.19B)
46% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$39.2M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$34.9M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$26.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$23.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$63.5M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$22.8M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$20.6M |
| 4 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$17.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$17.1M |
AERI Hedge Fund Activity: Q4 2018 in Review
160 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2018, worth a combined $1.76B — down 40% from $2.96B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of AERI and 19 opened new positions — a net loss of 16 holders — while 56 trimmed existing stakes and 65 added.
The largest buyer was Bank of New York Mellon, adding an estimated $39.2M. The largest seller was HealthCor Management, exiting entirely with an estimated $63.5M sold.
- 160 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2018, down from 176 in Q3 2018.
- Funds reported $1.76B of Aerie Pharmaceuticals stock for Q4 2018, down 40% quarter-over-quarter.
- 19 funds opened new Aerie Pharmaceuticals positions in Q4 2018 and 35 closed out, a net change of -16 holders.
- The largest Aerie Pharmaceuticals buyer in Q4 2018 was Bank of New York Mellon, an estimated $39.2M added.
- The largest Aerie Pharmaceuticals seller in Q4 2018 was HealthCor Management, an estimated $63.5M sold.
Based on aggregated 13F filings for Q4 2018.